Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Catabolic factors in cancer cachexia

M J Tisdale1, T M McDevitt, P T Todorov

  • 1Pharmaceutical Science Institute, Aston University, Birmingham, United Kingdom.

In Vivo (Athens, Greece)
|March 1, 1996
PubMed
Summary

Researchers purified a lipid mobilizing factor from a mouse colon tumor causing cachexia. Antibodies against this factor were found in tumor-bearing mice and cancer patients, suggesting its role in tumor growth and cachexia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia.

The Journal of frailty & aging·2016
Same author

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.

British journal of cancer·2014
Same author

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Cell death and differentiation·2013
Same author

Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle.

Cellular signalling·2012
Same author

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

Leukemia·2011
Same author

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

British journal of cancer·2011

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Cancer cachexia is a complex metabolic syndrome characterized by involuntary weight loss.
  • A lipid mobilizing factor (LMF) has been implicated in the pathogenesis of cachexia.

Purpose of the Study:

  • To purify and characterize the LMF from a cachexia-inducing mouse colon adenocarcinoma (MAC16).
  • To investigate the immunological response to the LMF and its potential role in tumor growth and cachexia.

Main Methods:

  • Purification of LMF using ion exchange, exclusion, and reverse-phase chromatography.
  • Western blotting and antibody detection in mouse serum and human urine.
  • Generation and testing of a monoclonal antibody against the LMF.

Main Results:

  • A 3,500-fold purification of LMF was achieved, with the active component identified as a 24 kDa protein.
  • Antibodies against the 24 kDa antigen were detected in MAC16 tumor-bearing mice and cancer cachexia patients, but not in controls.
  • A monoclonal antibody against the 24 kDa antigen attenuated cachexia and inhibited tumor growth in mice.

Conclusions:

  • The M(r) 24 kDa antigen is likely a key mediator of lipid mobilization in cancer cachexia.
  • This antigen may play a significant role in both tumor growth and the development of cachexia.
  • The 24 kDa antigen represents a potential therapeutic target for managing cancer cachexia.

Related Experiment Videos